Estrogen receptor (ER)-negative breast cancer shows a higher incidence in women of African ancestry compared to women of European ancestry. In search of common risk alleles for ERnegative breast cancer, we combined genome-wide association study (GWAS) data from women of African ancestry (1,004 ER-negative cases and 2,745 controls) and European ancestry (1,718 ER-negative cases and 3,670 controls), with replication testing conducted in an additional 2,292 ER-negative cases and 16,901 controls of European ancestry. We identified a common risk variant for ER-negative breast cancer at the TERT-CLPTM1L locus on chromosome 5p15 (rs10069690: per-allele odds ratio (OR) = 1.18 per allele, P = 1.0 × 10 −10 ). The variant was also significantly associated with triple-negative (ER-negative, progesterone receptor (PR)-negative and human epidermal growth factor-2 (HER2)-negative) breast cancer (OR = 1.25, P = 1.1 × 10 −9 ), particularly in younger women (<50 years of age) (OR = 1.48, P = 1.9 × 10 −9 ). Our results identify a genetic locus associated with estrogen receptor negative breast cancer subtypes in multiple populations.
Compared to women of European ancestry, women of African descent are more likely to be diagnosed with ER-negative breast cancer 1 . ERnegative tumors and triple-negative tumors are observed at even higher rates among African women currently residing in Africa 2 , suggesting a genetic component to the high risk of ER-negative phenotypes in women of African descent. Similarly, ER-negative breast cancers and triple-negative breast cancers are also the predominant histological subtypes in women with germline mutations in BRCA1 (ref. 3) . The enrichment for ER-negative disease in this genetically predisposed population also suggests the existence of additional genetic factors that contribute to the risk of ER-negative disease.
Support for the presence of these factors was recently provided by a GWAS of breast cancer in BRCA1 mutation carriers, in which a common risk variant for ER-negative breast cancer on chromosome 19p13 was identified that also was significantly associated with ER-negative and triple-negative disease in the general population 4 .
To search for genetic risk factors for ER-negative breast cancer phenotypes, we combined results from a GWAS of breast cancer in AfricanAmerican women (African American Breast Cancer Consortium (AABC): 3,016 cases (1,004 with ER-negative disease) and 2,745 controls) with results from a GWAS of triple-negative breast cancer in women of European ancestry (Triple-Negative Breast Cancer Consortium (TNBCC): 1,718 cases and 3,670 controls). Genotyping in AABC was conducted with the Illumina Infinium 1M Duo. In TNBCC, cases were genotyped with the Illumina 660W array, a subset of cases from the Mammary Carcinoma Risk Factor Investigation (MARIE) component were genotyped using the Illumina CNV370 SNP array, and cases and controls from the Helsinki Breast Cancer Study (HEBCS) component were genotyped using the Illumina 550-Duo SNP array. Genotypes of TNBCC cases were compared with GWAS data for publicly available controls (Online Methods). Both studies imputed genotypes for common SNPs in phase 2 HapMap populations (release 21) (Supplementary Table 1 and Online Methods). A total of 3,154,485 SNPs, genotyped and imputed, were analyzed in stage 1 of the meta-analysis.
We observed little evidence of inflation in the test statistics in AABC (λ = 1.01) or TNBCC (λ = 1.04) or in the meta-analysis of the two GWAS (λ = 1.02; Supplementary Fig. 1 ). In the combined results, only SNP rs10069690 (NCBI36/hg18, chr5:1,332,790) located in intron 4 of the TERT gene (encoding telomerase reverse transcriptase) at chromosome 5p15 showed a genome-wide significant association with ER-negative breast cancer (AABC: OR per allele = 1.32, P = 1. P = 1.0 × 10 −8 ). Whereas SNP rs10069690 was genotyped in AABC, it was imputed in TNBCC (R 2 = 0.55). To verify the imputed genotypes and the significance of the association in TNBCC, we re-genotyped rs10069690 in available DNA samples from 2,963 TNBCC cases and 1,632 study-specific TNBCC controls (Online Methods). Although the overlapping samples between the TNBCC GWAS and the regenotyping study showed that the quality of imputation for rs10069690 in the GWAS was poor (Online Methods), the association with ERnegative breast cancer for rs10069690 remained statistically significant in the larger re-genotyped TNBCC sample (OR = 1.18, P = 1.0 × 10 −3 ; Table 1 and Fig. 1 ) and in the new combined results for AABC and the re-genotyped TNBCC sample (OR = 1.24, P = 1.6 × 10 −8 ).
To further confirm the association at 5p15, we genotyped SNP rs10069690 in women of European ancestry, which included 8,365 cases (1,359 ER negative) and 10,935 controls from the US National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) and 6,182 cases (933 ER negative) and 5,966 controls from Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH). Evidence for replication was observed for rs10069690 and ER-negative breast cancer in both studies (BPC3: OR = 1.09, P = 0.077; SEARCH: OR = 1.21, P = 6.9 × 10 −4 ; Table 1 ).
In combining the results across all studies (6,009 ER-negative cases and 20,708 controls with genotype data), rs10069690 was significantly associated with an increased risk of ER-negative breast cancer (OR = 1.18, 95% confidence interval (CI), 1.13-1.25; P = 1.0 × 10 −10 ; Table 1 ). The risk for heterozygote and homozygote carriers was 1.15 (95% CI, 1.06-1.23) and 1.46 (95% CI, 1.29-1.64), respectively. We observed little evidence of heterogeneity for the reported association for this variant by study or country in AABC (test for heterogeneity, p het = 0.86), TNBCC (p het = 0.85) or BPC3 (p het = 0.37; Supplementary Table 2) .
In an analysis of ER-positive cases, rs10069690 was only weakly associated with risk in African Americans (AABC: 1,558 ER-positive cases and 2,743 controls with genotype data, OR = 1.08, P = 0.10) and in women of European ancestry (BPC3: 4,890 ER-positive cases and 10,397 controls, OR = 1.03, P = 0.31; SEARCH: 3,534 ER positive cases and 5,966 controls, OR = 1.03, P = 0.37; combined for all populations: OR = 1.04, P = 0.06, p het = 0.64). The statistical power to detect an OR of 1.18 (observed for ER-negative disease) for ERpositive disease was >99% in the combined sample (9,982 cases and 19,106 controls), assuming the risk allele frequency of 0.26 in people of European decent. This result suggests that the association with breast cancer might be specific for ER-negative subtypes (P value for case-only test of ER negative versus ER positive = 1.7 × 10 −4 ).
We further stratified the cases by HER2 status to assess whether this region may be a risk locus for triple-negative disease. In AABC, BPC3 and SEARCH the association with rs10069690 was greater for triple-negative tumors than for ER-negative, PR-negative, HER2-positive tumors (Table 2) , and, in combining all studies, including TNBCC, the association with rs10069690 was significantly greater for triple-negative disease (3,707 triple-negative cases and 19,728 controls with genotype data, OR = 1.25, P = 1.1 × 10 −9 ; 376 ER-negative, PR-negative, HER2-positive cases and 18,126 controls, OR = 1.03, P = 0.71; P value for case-only test = 0.010). The association with rs10069690 was also observed to be significantly greater for ER-negative and triple-negative disease at younger ages (<50 years: ER negative, Figure 1 A regional plot of the −log 10 P values for SNPs at the chromosome 5p15 risk locus from the meta-analysis of the AABC and TNBCC stage 1 studies. SNP rs10069690 is designated with the purple diamonds. The colors depict the strength of the correlation (r 2 ) between SNP rs10069690 and the SNPs tested in the region. The correlation is estimated using 1000 Genomes Project (1KGP) data for the HapMap CEU population (June 2010). Squares are SNPs that were genotyped in AABC and TNBCC. Circles are SNPs that were genotyped in one study and imputed in the other or imputed in both studies. The blue line indicates the recombination rates in centimorgans (cM) per megabase (Mb). Also shown are the SNP Build 36 coordinates and genes in the region. l e t t e r s 1 2 1 2 VOLUME 43 | NUMBER 12 | DECEMBER 2011 Nature GeNetics l e t t e r s OR = 1.32, P = 1.4 × 10 −8 ; triple negative, OR = 1.48, P = 1.9 × 10 −9 ; P for interaction with age = 0.035 and 3.2 × 10 −3 , respectively; Supplementary Supplementary Fig. 2 ) with variants found for serous ovarian cancer (rs7726159), glioma (rs2736100) and lung cancer (rs2736100, rs2735940) [12] [13] [14] . Aside from risk variant rs2853676 found for glioma 14 , which we found to be associated with risk in TNBCC (P = 0.014, r 2 = 0.05 with rs10069690), none of the known risk variants identified for other cancers in the TERT-CLPTM1L region was significantly associated with breast cancer risk in TNBCC or AABC. Although rs7726159 was not tested in AABC or TNBCC (as it is not on the Illumina arrays or in HapMap), it is noteworthy that the first common risk variant identified for ER-negative breast cancer, at chromosome 19p13, is also associated with risk for serous ovarian cancer 15 . The TERT gene encodes the catalytic subunit of telomerase, which controls telomere length, a process linked with genomic instability and implicated in tumorigenesis. Sequencing of the coding exons of TERT in 96 African-American women (Online Methods) did not reveal a coding variant strongly correlated with rs10069690. The TERT locus may highlight another biological process common to the pathogenesis of ER-negative breast cancer subtypes and serous ovarian cancer that is also shared with other cancers.
Identification of the variant directly responsible for the association will be required to fully address the extent to which this locus contributes to the greater incidence of ER-negative and triple-negative tumors in women of African ancestry. However, it is notable that the risk allele frequency of rs10069690 is greater in African American women (frequency, 0.57) than in women of European ancestry (frequency, 0.26). If this variant is an equally good surrogate for the biologically functional allele in each population, then this locus may be responsible for a 15% (95% CI, 10-20%) higher incidence rate of ER-negative or triple-negative breast cancer in women of African compared to European ancestry (Online Methods). Larger studies with well-characterized tumor pathology information will be needed to determine whether the association we observed applies to all ERnegative disease or just the triple-negative subtype. Our findings provide further support for the presence of genetic susceptibility to ER-negative breast cancer subtypes and demonstrate the importance of discovery efforts in multiple populations.
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